[pubmed] Eculizumab treatment for myasthenia gravis subgroups: 2021 update
Posté : 25 nov. 2021 12:00
J Neuroimmunol. 2021 Nov 18;362:577767. doi: 10.1016/j.jneuroim.2021.577767. Online ahead of print.
ABSTRACT
Eculizumab is a recombinant humanized monoclonal antibody that targets the complement protein C5, inhibiting its cleavage into C5a and C5b and ultimately preventing the formation of C5b-9 membrane attack complex (MACs), thereby protecting the neuromuscular junction from the damage of complement activation. In 2017, eculizumab became the second FDA-approved medication for AchR-positive generalized myasthenia gravis (gMG) patients based on the successful results of a randomized, double-blinded, placebo-controlled, phase 2, phase 3 study (the REGAIN trial) and its open-label extension study. Despite the efficacy of eculizumab in treating AchR antibody-positive refractory gMG was demonstrated in the REGAIN study, there is few information on its efficacy in other subgroup of MG patients including seronegative MG, thymoma-associated MG and MG crisis. This narrative review summarizes current clinical studies of eculizumab in these refractory gMG patients, with a focus on the therapeutic efficacy and tolerability in different subgroup of MG.
PMID:34823117 | DOI:10.1016/j.jneuroim.2021.577767
Source: https://pubmed.ncbi.nlm.nih.gov/3482311 ... 5&v=2.15.0